<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Nektar Therapeutics — News on 6ix</title>
<link>https://6ix.com/company/nektar-therapeutics</link>
<description>Latest news and press releases for Nektar Therapeutics on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 23 Apr 2026 20:15:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/nektar-therapeutics" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835a24078dffbe2df109a55.webp</url>
<title>Nektar Therapeutics</title>
<link>https://6ix.com/company/nektar-therapeutics</link>
</image>
<item>
<title>Nektar Therapeutics Announces Closing of $373.8 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares</title>
<link>https://6ix.com/company/nektar-therapeutics/news/nektar-therapeutics-announces-closing-of-dollar3738-million-public-offering-including-full-exercise-of-underwriters-option-to-purchase-additional-shares</link>
<guid isPermaLink="true">https://6ix.com/company/nektar-therapeutics/news/nektar-therapeutics-announces-closing-of-dollar3738-million-public-offering-including-full-exercise-of-underwriters-option-to-purchase-additional-shares</guid>
<pubDate>Thu, 23 Apr 2026 20:15:00 GMT</pubDate>
<description>Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today announced the closing of its underwritten public offering of $373.8 million of shares of its common stock. Nektar sold 4,062,500 shares of common stock in the offering, which includes 529,891 shares sold upon exercise in full by the underwriters of their option to purchase additional shares of common stock in the offering. The shares of common stock were sold at</description>
</item>
<item>
<title>Nektar Therapeutics Announces Pricing of Upsized $325 Million Public Offering</title>
<link>https://6ix.com/company/nektar-therapeutics/news/nektar-therapeutics-announces-pricing-of-upsized-dollar325-million-public-offering-3</link>
<guid isPermaLink="true">https://6ix.com/company/nektar-therapeutics/news/nektar-therapeutics-announces-pricing-of-upsized-dollar325-million-public-offering-3</guid>
<pubDate>Tue, 21 Apr 2026 04:00:00 GMT</pubDate>
<description>SAN FRANCISCO, April 21, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of</description>
</item>
<item>
<title>52-Week Topline Results from 16-Week Blinded Treatment Extension of REZOLVE-AA Demonstrate Deepening of Responses in Severe-to-Very-Severe Alopecia Areata with Rezpegaldesleukin</title>
<link>https://6ix.com/company/nektar-therapeutics/news/52-week-topline-results-from-16-week-blinded-treatment-extension-of-rezolve-aa-demonstrate-deepening-of-responses-in-severe-to-very-severe-alopecia-areata-with-rezpegaldesleukin</link>
<guid isPermaLink="true">https://6ix.com/company/nektar-therapeutics/news/52-week-topline-results-from-16-week-blinded-treatment-extension-of-rezolve-aa-demonstrate-deepening-of-responses-in-severe-to-very-severe-alopecia-areata-with-rezpegaldesleukin</guid>
<pubDate>Mon, 20 Apr 2026 11:30:00 GMT</pubDate>
<description>Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today announced new results from a blinded 16-week treatment extension period in its Phase 2b REZOLVE-AA study. The study is evaluating investigational rezpegaldesleukin, a first-in-class IL-2 pathway agonist and regulatory T-cell (Treg) biologic, in patients with severe-to-very-severe alopecia areata.</description>
</item>
<item>
<title>Nektar to Hold Conference Call to Discuss 52-Week Topline Results from the 16-Week Extension Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on April 20, 2026</title>
<link>https://6ix.com/company/nektar-therapeutics/news/nektar-to-hold-conference-call-to-discuss-52-week-topline-results-from-the-16-week-extension-treatment-period-for-its-rezolve-aa-phase-2b-study-of-rezpegaldesleukin-in-alopecia-areata-on-april-20-2026</link>
<guid isPermaLink="true">https://6ix.com/company/nektar-therapeutics/news/nektar-to-hold-conference-call-to-discuss-52-week-topline-results-from-the-16-week-extension-treatment-period-for-its-rezolve-aa-phase-2b-study-of-rezpegaldesleukin-in-alopecia-areata-on-april-20-2026</guid>
<pubDate>Sun, 19 Apr 2026 16:00:00 GMT</pubDate>
<description>Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today announced it will host an investor call and live webcast to review 52-week topline results from the 16-week extension treatment period of the ongoing Phase 2b REZOLVE-AA clinical trial of investigational rezpegaldesleukin, a regulatory T-cell (Treg) proliferator, for severe-to-very-severe alopecia areata on Monday, April 20, 2026 at 8:00 am ET / 5:00 am PT.</description>
</item>
<item>
<title>Data from Phase 2b REZOLVE-AD and REZOLVE-AA Studies of Rezpegaldesleukin Presented at 2026 American Academy of Dermatology Annual Meeting</title>
<link>https://6ix.com/company/nektar-therapeutics/news/data-from-phase-2b-rezolve-ad-and-rezolve-aa-studies-of-rezpegaldesleukin-presented-at-2026-american-academy-of-dermatology-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/nektar-therapeutics/news/data-from-phase-2b-rezolve-ad-and-rezolve-aa-studies-of-rezpegaldesleukin-presented-at-2026-american-academy-of-dermatology-annual-meeting</guid>
<pubDate>Sat, 28 Mar 2026 04:00:00 GMT</pubDate>
<description>Rezpegaldesleukin demonstrates statistically significant improvement in mean percent EASI improvement across both moderate and severe atopic dermatitis</description>
</item>
<item>
<title>Data from Phase 2b Studies for Rezpegaldesleukin Accepted for Two Oral Presentations at the 2026 American Academy of Dermatology Annual Meeting</title>
<link>https://6ix.com/company/nektar-therapeutics/news/data-from-phase-2b-studies-for-rezpegaldesleukin-accepted-for-two-oral-presentations-at-the-2026-american-academy-of-dermatology-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/nektar-therapeutics/news/data-from-phase-2b-studies-for-rezpegaldesleukin-accepted-for-two-oral-presentations-at-the-2026-american-academy-of-dermatology-annual-meeting</guid>
<pubDate>Fri, 20 Mar 2026 04:00:00 GMT</pubDate>
<description>SAN FRANCISCO, March 20, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that data from the ongoing Phase 2b studies of</description>
</item>
<item>
<title>Nektar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/nektar-therapeutics/news/nektar-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-65</link>
<guid isPermaLink="true">https://6ix.com/company/nektar-therapeutics/news/nektar-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-65</guid>
<pubDate>Thu, 12 Mar 2026 04:00:00 GMT</pubDate>
<description>SAN FRANCISCO, March 12, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter ended December 31,</description>
</item>
<item>
<title>Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2025 on Thursday, March 12, 2026, After Close of U.S.-Based Financial Markets</title>
<link>https://6ix.com/company/nektar-therapeutics/news/nektar-to-announce-financial-results-for-the-fourth-quarter-and-year-ended-2025-on-thursday-march-12-2026-after-close-of-us-based-financial-markets</link>
<guid isPermaLink="true">https://6ix.com/company/nektar-therapeutics/news/nektar-to-announce-financial-results-for-the-fourth-quarter-and-year-ended-2025-on-thursday-march-12-2026-after-close-of-us-based-financial-markets</guid>
<pubDate>Thu, 26 Feb 2026 05:00:00 GMT</pubDate>
<description>SAN FRANCISCO, Feb. 26, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended</description>
</item>
<item>
<title>Nektar Therapeutics to Participate in Two Investor Conferences in March</title>
<link>https://6ix.com/company/nektar-therapeutics/news/nektar-therapeutics-to-participate-in-two-investor-conferences-in-march</link>
<guid isPermaLink="true">https://6ix.com/company/nektar-therapeutics/news/nektar-therapeutics-to-participate-in-two-investor-conferences-in-march</guid>
<pubDate>Tue, 24 Feb 2026 05:00:00 GMT</pubDate>
<description>SAN FRANCISCO, Feb. 24, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that company management will be participating in the TD Cowen</description>
</item>
<item>
<title>Nektar Therapeutics Announces Research Collaboration with UCSF and Dr. Stephen Hauser for NKTR-0165, a Tumor Necrosis Factor Receptor 2 (TNFR2) Antibody, in Multiple Sclerosis</title>
<link>https://6ix.com/company/nektar-therapeutics/news/nektar-therapeutics-announces-research-collaboration-with-ucsf-and-dr-stephen-hauser-for-nktr-0165-a-tumor-necrosis-factor-receptor-2-tnfr2-antibody-in-multiple-sclerosis</link>
<guid isPermaLink="true">https://6ix.com/company/nektar-therapeutics/news/nektar-therapeutics-announces-research-collaboration-with-ucsf-and-dr-stephen-hauser-for-nktr-0165-a-tumor-necrosis-factor-receptor-2-tnfr2-antibody-in-multiple-sclerosis</guid>
<pubDate>Tue, 17 Feb 2026 05:00:00 GMT</pubDate>
<description>SAN FRANCISCO, Feb. 17, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced an academic research collaboration with the University of</description>
</item>
<item>
<title>Nektar Therapeutics Announces Closing of $460 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares</title>
<link>https://6ix.com/company/nektar-therapeutics/news/nektar-therapeutics-announces-closing-460-211500866</link>
<guid isPermaLink="true">https://6ix.com/company/nektar-therapeutics/news/nektar-therapeutics-announces-closing-460-211500866</guid>
<pubDate>Fri, 13 Feb 2026 21:15:00 GMT</pubDate>
<description>Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherapy, today announced the closing of its underwritten public offering of $460 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants. Nektar sold 7,637,931 shares of common stock in the offering, which includes 1,034,482 shares sold upon exercise in full by the underwriters of their option to p</description>
</item>
<item>
<title>Nektar Therapeutics Announces Pricing of Upsized $400 Million Public Offering</title>
<link>https://6ix.com/company/nektar-therapeutics/news/nektar-therapeutics-announces-pricing-upsized-032300008</link>
<guid isPermaLink="true">https://6ix.com/company/nektar-therapeutics/news/nektar-therapeutics-announces-pricing-upsized-032300008</guid>
<pubDate>Thu, 12 Feb 2026 03:23:00 GMT</pubDate>
<description>Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherapy, today announced the pricing of its upsized underwritten public offering of $400 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants. Nektar is selling 6,603,449 shares of common stock and 293,103 pre-funded warrants in the offering. The shares of common stock are being sold at a public</description>
</item>
<item>
<title>New REZOLVE-AD Maintenance Data in Atopic Dermatitis Demonstrate Rezpegaldesleukin Resulted in Durable and New Responses Across Key Disease Measurements with Both Monthly and Quarterly Dosing</title>
<link>https://6ix.com/company/nektar-therapeutics/news/rezolve-ad-maintenance-data-atopic-120000860</link>
<guid isPermaLink="true">https://6ix.com/company/nektar-therapeutics/news/rezolve-ad-maintenance-data-atopic-120000860</guid>
<pubDate>Tue, 10 Feb 2026 12:00:00 GMT</pubDate>
<description>Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today announced positive results from the 36-week blinded maintenance period of the 52-week REZOLVE-AD study of rezpegaldesleukin, a novel regulatory T-cell (Treg) biologic, in patients with moderate-to-severe atopic dermatitis (AD).</description>
</item>
<item>
<title>Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Maintenance Period for its REZOLVE-AD Phase 2b Study of Rezpegaldesleukin in Atopic Dermatitis on February 10, 2026</title>
<link>https://6ix.com/company/nektar-therapeutics/news/nektar-hold-conference-call-discuss-211500776</link>
<guid isPermaLink="true">https://6ix.com/company/nektar-therapeutics/news/nektar-hold-conference-call-discuss-211500776</guid>
<pubDate>Mon, 09 Feb 2026 21:15:00 GMT</pubDate>
<description>Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of novel immunology therapies, today announced it will host an investor call and live webcast to review topline results from the 36-week maintenance period of the ongoing Phase 2b REZOLVE-AD clinical trial of investigational rezpegaldesleukin, a regulatory T-cell (Treg) proliferator, for moderate-to-severe atopic dermatitis on Tuesday, February 10, 2026 at 8:00 am ET / 5:00 am PT.</description>
</item>
<item>
<title>Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/nektar-therapeutics/news/nektar-therapeutics-reports-inducement-grants-211000068</link>
<guid isPermaLink="true">https://6ix.com/company/nektar-therapeutics/news/nektar-therapeutics-reports-inducement-grants-211000068</guid>
<pubDate>Fri, 30 Jan 2026 21:10:00 GMT</pubDate>
<description>Nektar Therapeutics (NASDAQ: NKTR) today announced that, on January 21, 2026, the Organization and Compensation Committee of Nektar's Board of Directors granted non-qualified stock options to purchase 1,600 shares of its common stock to one newly-hired employee under Nektar's 2025 Inducement Plan.</description>
</item>
<item>
<title>REZOLVE-AA Phase 2b Study of Rezpegaldesleukin Establishes Proof-of-Concept in Patients with Severe-to-Very-Severe Alopecia Areata</title>
<link>https://6ix.com/company/nektar-therapeutics/news/rezolve-aa-phase-2b-study-rezpegaldesleukin-establishes-proof-concept-patients-severe</link>
<guid isPermaLink="true">https://6ix.com/company/nektar-therapeutics/news/rezolve-aa-phase-2b-study-rezpegaldesleukin-establishes-proof-concept-patients-severe</guid>
<pubDate>Tue, 16 Dec 2025 05:00:00 GMT</pubDate>
<description>Achieved target product profile on the primary endpoint, with a mean percent reduction in SALT score at 36 weeks of 28.2% in the 24 µg/kg arm versus 11.2% in</description>
</item>
<item>
<title>Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Induction Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on December 16, 2025</title>
<link>https://6ix.com/company/nektar-therapeutics/news/nektar-hold-conference-call-discuss-topline-results-36-week-induction-treatment</link>
<guid isPermaLink="true">https://6ix.com/company/nektar-therapeutics/news/nektar-hold-conference-call-discuss-topline-results-36-week-induction-treatment</guid>
<pubDate>Mon, 15 Dec 2025 05:00:00 GMT</pubDate>
<description>SAN FRANCISCO, Dec. 15, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel</description>
</item>
<item>
<title>New Data from REZOLVE-AD Study of Rezpegaldesleukin Presented in Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting</title>
<link>https://6ix.com/company/nektar-therapeutics/news/new-data-rezolve-ad-study-rezpegaldesleukin-presented-late-breaking-oral-abstract</link>
<guid isPermaLink="true">https://6ix.com/company/nektar-therapeutics/news/new-data-rezolve-ad-study-rezpegaldesleukin-presented-late-breaking-oral-abstract</guid>
<pubDate>Sat, 08 Nov 2025 05:00:00 GMT</pubDate>
<description>Statistically significant and clinically meaningful improvements in mean ACQ-5 scores were reported at week 16 versus placebo in patients who had atopic</description>
</item>
<item>
<title>Nektar Therapeutics Reports Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/nektar-therapeutics/news/nektar-therapeutics-reports-third-quarter-2025-financial-results-2025-11-06</link>
<guid isPermaLink="true">https://6ix.com/company/nektar-therapeutics/news/nektar-therapeutics-reports-third-quarter-2025-financial-results-2025-11-06</guid>
<pubDate>Thu, 06 Nov 2025 05:00:00 GMT</pubDate>
<description>SAN FRANCISCO, Nov. 6, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the third quarter ended September 30,</description>
</item>
<item>
<title>Nektar Therapeutics to Participate in the Jefferies Global Healthcare Conference in London</title>
<link>https://6ix.com/company/nektar-therapeutics/news/nektar-therapeutics-participate-jefferies-global-healthcare-conference-london-2025-10</link>
<guid isPermaLink="true">https://6ix.com/company/nektar-therapeutics/news/nektar-therapeutics-participate-jefferies-global-healthcare-conference-london-2025-10</guid>
<pubDate>Thu, 30 Oct 2025 04:00:00 GMT</pubDate>
<description>SAN FRANCISCO, Oct. 30, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that company management will be webcasting its participation</description>
</item>
</channel>
</rss>